Antitumor Effect of Dendritic Cell Modified by Gp96-peptide Complex

杨威,曹春霞,刘青光,于良,马清涌,潘承恩
DOI: https://doi.org/10.3760/j.issn:1001-9030.2004.08.012
2004-01-01
Abstract:Objective To investigate the effect of antitumor effect of dendritic cells (DC) modified by Gp96-peptide complexs in vitro and in vivo. Methods Gp96-peptide complexes were obtained from H22 liver cancer cells in mice. DC were cultured from bone marrow cells and modified by Gp96-peptide complexes. Spleen lymphocytes of mice were activated by modified DC and the cytotoxicity was detected by 51Cr release method. Modified DC, Gp96-peptide complexes and inactivated H22 cells were injected into mice bearing H22 liver cancer cells to observe the levels of IL-10, IFN-γ in serum and the alteration of proportions of CD_8~+ -IFNγ~+ and CD_8~+ -IL-10~+ cells, CD_4~+ -IFNγ~+ and CD_4~+ -IL-10~+ cells. Results DC modified by Gp96-peptide complexes could activate spleen lymphocyte and the latter could specifically kill H22 cells but not Ehrilich ascites carcinoma cells. Modified DC could improve the host' s antitumor immune response and the proportions of Th1 cells, so inhibiting tumor growth. Conclusion Gp96-peptide complexes can activate DC effectively, making DC a good vaccine.
What problem does this paper attempt to address?